Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer? by Paulsen, Erna-Elise et al.
Carcinogenesis, 2020, Vol. 41, No. 12, 1671–1681
doi:10.1093/carcin/bgaa105
Advance Access publication October 9, 2020
Original Article
1671
Received: July 18, 2020; Revised: October 1, 2020; Accepted: October 5, 2020
© The Author(s) 2020. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any  
medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Original Article
Digitally quantified CD8+ cells: the best candidate 
marker for an immune cell score in non-small cell 
lung cancer?
Thomas K.Kilvaer1,2,*,  Erna-Elise Paulsen2,3, Sigve Andersen1,2, Mehrdad Rakaee2,4, 
Roy M.Bremnes1,2, Lill-Tove Rasmussen Busund4,5 and Tom Donnem1,2
1Department of Oncology, University Hospital of North Norway, Tromso, Norway, 2Department of Clinical Medicine, UiT The 
Arctic University of Norway, Tromso, Norway, 3Department of Pulmonary Medicine, University Hospital of North Norway, 
Tromso, Norway, 4Department of Medical Biology, UiT The Arctic University of Norway, Tromso, Norway and 5Department of 
Clinical Pathology, University Hospital of North Norway, Tromso, Norway
*To whom correspondence should be addressed. Department of Oncology, University Hospital of North Norway, 9038 Tromso, Norway. Tel: +47 776 26 
765/+47 905 24 635; Fax: +47 77626779; Email: kilvaer@gmail.com
Abstract
The TNM classification is well established as a state-of-the-art prognostic and treatment-decision-making tool for 
non-small cell lung cancer (NSCLC) patients. However, incorporation of biological data may hone the TNM system. 
This article focuses on choosing and incorporating subsets of tissue-infiltrating lymphocyte (TIL), detected by specific 
immunohistochemistry and automatically quantified by open source software, into a TNM-Immune cell score (TNM-I) for 
NSCLC. We use common markers (CD3, CD4, CD8, CD20 and CD45RO) of TILs to identify TIL subsets in tissue micro-arrays 
comprising tumor tissue from 553 patients resected for primary NSCLC. The number of TILs is automatically quantified 
using open source software (QuPath). Their prognostic efficacy, alone and within a TNM-I model, is evaluated in all patients 
and histological subgroups. Compared with previous manual semi-quantitative scoring of TILs in the same cohort, the 
present digital quantification proved superior. As a proof-of-concept, we construct a TNM-I, using TNM categories and the 
CD8+ TIL density. The TNM-I is an independent prognosticator of favorable diagnosis in both the overall cohort and in the 
main histological subgroups. In conclusion, CD8+ TIL density is the most promising candidate marker for a TNM-I in NSCLC. 
The prognostic efficacy of the CD8+ TIL density is strongest in lung squamous cell carcinomas, whereas both CD8+ TILs and 
CD20+ TILs, or a combination of these, may be candidates for a TNM-I in lung adenocarcinoma. Furthermore, based on the 
presented results, digital quantification is the preferred method for scoring TILs in the future.
Introduction
Lung cancer, with a global estimate of 1.7 million patients who 
will succumb to the disease in 2018, remains the second and 
most common cause of cancer-related deaths, in both women 
and men (1). Lung cancer is mainly divided into two entities, 
small cell lung cancer and non-small cell lung cancer (NSCLC); 
of which, the latter comprises nearly 85% of all cases (2). 
Currently, patient prognoses are best predicted by the TNM clas-
sification system, describing the extent of the primary tumor (T), 
involved lymph nodes (N) and metastatic disease (M). Patients 
are categorized from stages I  (localized cancer without lymph 
node involvement) to IV (metastatic disease). According to the 
current ESMO guidelines for early and locally advanced NSCLC, 
important clinical cutoffs are as follows: stage IB/IIA and stage 
IIIA/IIIB, representing the thresholds for adjuvant chemotherapy 
and treatment with curable versus palliative intent, respectively 
(3).
Although the TNM system incorporates essential information 
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incorporating biomarkers directly related to cancer biology, devel-
opment and progression (2). In the last two decades, tremendous 
effort has been put into this research area, and a plethora of po-
tential biomarkers have been explored (2). For NSCLC patients, this 
pivotal work has provided several molecular targets/biomarkers 
implemented in clinical practice for predicting efficacy of treatment 
with targeted therapies and immunotherapy, though predomin-
antly for subgroups of patients receiving palliative treatment (2,4,5).
In the last decade, clinical cancer research has shifted its 
focus, from mainly targeting examining tumor cell features, to 
exploring the multitude of other players in the tumor micro-
environment (6). Especially, the increasing understanding of 
tumor–immune–system interactions has prompted new treat-
ment strategies, leading to better treatment options and, in the 
case of melanoma, the potential cure of a small subset of pa-
tients (7–9). Checkpoint inhibitors constitute an elegant concept 
wherein the drugs unleash the body’s own immune cells primed 
against neoplastic cells (7). Although research in melanoma pa-
tients has paved the road for immunotherapy in general, NSCLC 
trials have been in the frontline exploring biomarkers predictive 
of immunotherapy efficacy (4,5,7–9). Programmed death re-
ceptor 1 ligand (PD-L1) has hitherto proven to be the most re-
liable biomarker for this purpose (4,5). With this background, 
incorporation of immune information seems a logical step to 
further improve NSCLC prognostication. For colorectal cancer 
(CRC), Galon et al. have found the immune contexture to provide 
prognostic information equal or superior to the established TNM 
(10). More specifically, they found that an index composed of the 
presence or absence of tumor infiltrating lymphocytes (TILs), ex-
pressing the CD3+ pan-T-cell marker and/or the CD8+ cytotoxic 
T-cell marker in the tumor center and periphery, provides highly 
specific and sensitive prognostic information (10). As a conse-
quence, they introduced the Immunoscore® (Immunoscore® is 
a registered trademark owned by INSERM) with the goal of sup-
plementing TNM for CRC (10). A similar initiative is in place for 
breast cancer (11). In NSCLC, several large studies have estab-
lished different immune-cell subsets as prognostic indicators, 
and, as in CRC, the most promising candidate markers up to 
date are CD3+, CD8+ and CD45RO+ expressing TILs (12–16).
We are currently working toward an implementation of 
a combined TNM-Immune cell score, a TNM-I, for NSCLC. In 
this study, we explore strategies for implementing a TNM-I for 
NSCLC, leveraging previous semi-quantitative as well as current 
digital, evaluation of CD3, CD4, CD8, CD20 and CD45RO in tissue 
micro-arrays (TMAs) of a cohort of 553 retrospectively collected 
primary tumors from NSCLC patients.
Materials and methods
Patients and clinical samples
The study population consisted of 553 consecutive NSCLC patients re-
sected in 1990–2010 at the University Hospital of North-Norway (N = 295) 
and the Nordland Central Hospital (N = 258). Detailed information on the 
study population is previously published (17).
Tissue micro-array construction and 
immunohistochemistry
All tissue samples were reviewed by an experienced pathologist. The most 
representative areas containing tumor tissue was marked on the hema-
toxylin and eosin slide and sampled for TMA blocks. The TMAs were as-
sembled using a tissue-arraying instrument (Beecher Instruments, Silver 
Springs, MD). The methodology is well documented (12,14,18). Briefly, a 
total of two stroma and tumor cores were sampled for each patient, re-
spectively. The staining methods for immunohistochemistry utilized in 
this study are all validated and previously published (12,14).
Semi-quantitative scoring of immunohistochemistry
Representative and viable tissue sections were reviewed using a light 
microscope. The stromal and tumor compartments were scored for CD3+, 
CD4+, CD8+, CD20+ and CD45RO+ separately. For scoring TILs in the tumor 
compartment, a five-category scale with the following levels according to 
the percentage of positive cells was used: 0: <1%, 1: 1%–5%, 2: 6%–25%, 3: 
26%–50%, 4: >50%. For scoring TILs in the stromal compartment, a four-
category scale with the following levels according to the percentage of 
positive cells was used for all markers: 0: 0%–5%, 1: 6%–25%, 2: 26%–50%, 
3: 50%. An exception was CD20 in the stromal compartment, for which the 
previously described five-category scale was used. When assessing a given 
core, the observers were blinded to each other’s scores, clinical variables 
and patient’s outcome.
Digital scoring of immunohistochemistry
TMA slides were digitized using a Pannoramic 250 Flash III (3DHistech, 
Budapest, Hungary) slide scanner and processed in QuPath v.0.1.3 
(Queen’s University, Belfast, Northern Ireland). TMA slides were dearrayed 
and preprocessed according to Bankhead et al. (19). After dearraying, TMAs 
were manually curated. Cell detection was conducted using QuPath’s 
built-in ‘Positive cell detection’ (19). Figure 1 shows example cores for each 
marker, with and without overlay. Parameters for ‘Positive cell detection’ 
were tuned separately for each marker. Batch scripts are available in sup-
plementary materials and methods. For each core, the total number of 
positive cells, irrespective of localization, was divided by the tissue area 
yielding positive cells per mm2.
Statistical methods
All statistical analyses and visual representations were created using 
RStudio 1.2.5019 with R version 3.6.3 (20) and libraries ‘survival’ (21), ‘plyr’ 








LUSC lung squamous cell carcinoma
NSCLC non-small cell lung cancer
TILs tumor infiltrating lymphocytes
TMAs tissue micro-arrays
TNM-I TNM-Immune cell score
Figure 1. Low and high scores, with and without overlays for positive/negative 
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Interobserver reliability was calculated using a two-way random-effects 
model with an absolute agreement definition and Cohen’s kappa coeffi-
cient with equal weighting. Correlations were calculated using Pearson and 
Spearman methods for continuous and discrete variables, respectively. T-tests 
were utilized to examine the differences of continuous variables across 
groups. The Mann–Whitney U test was used to examine the association be-
tween distribution of different lymphocyte subsets across pathological stages.
Univariable survival analyses were conducted using the Kaplan–Meier 
method. Statistical difference between survival curves was assessed by 
the log-rank test. Disease-specific survival (DSS) was defined as the time 
from surgery to cancer-related death. Multivariable analyses, using the Cox 
proportional hazards model, were carried out to assess the independent 
value of pretreatment variables in the presence of other variables. Only 
variables with P < 0.25 from the univariable analyses, or deemed likely to 
influence outcome despite P-value, were explored in multivariable ana-
lyses. The significance level used was P < 0.05.
Ethical considerations
This study was approved by the Regional Committee for Medical and 
Health Research Ethics (Northern Norway, UNN: protocol ID: 2011/2503) 
and the need for patient consent waived. The National Data Inspection 
Board approved the collection and storing of the clinical database. The 
reporting of clinicopathological variables, survival data and biomarker ex-
pressions was conducted in accordance with the REMARK guidelines (27).
Results
Clinicopathological variables
Detailed information of the clinicopathological variables for the 
553 patients in the population is already published (17). Briefly, 
the median age at time of diagnosis was 67 years and the me-
dian survival of survivors was 86 months. The population con-
sisted of 32% females and the histological distribution was 307 
lung squamous cell carcinomas (LUSC), 239 lung adenocarcin-
omas (LUAD) and 7 other. One hundred and sixty-eight patients 
received either adjuvant radiotherapy or chemotherapy or both.
Expression of CD3+, CD4+, CD8+, CD20+ and CD45RO+ 
TILs, their interobserver variability and correlations 
between digital and semi-quantitative scores
CD3, CD4, CD8. CD20 and CD45RO were expressed on the sur-
face and in the cytoplasm of immune cells (Figure 1). All anti-
bodies performed to expectation (Figure  1). Interestingly, CD4, 
which was considered to perform poorly during visual scoring, 
was easy to interpret in the digital domain.
Between-scorer agreements for semi-quantitative scores are 
summarized in Supplementary Table S1A. The ICC scores were 
generally higher for stromal (0.87–0.94) versus tumor scores 
(0.64–0.81). This observation was also reflected in the between-
scorer Kappa values (0.62–0.77 stromal scores; 0.40–0.54 tumor 
scores).
Spearman’s rank correlations between digital and semi-
quantitative scores are summarized in Supplementary Table 
S1B. Since the semi-quantitative scoring was conducted in a 
microscope without annotation of the core of origin, only the 
final score for each patient, and not the score for each individual 
core, could be compared. Correlation coefficients were higher for 
digital and stromal scores (0.68–0.79) compared with digital and 
tumor scores (0.40–0.61).
Cutoff exploration and selection
All patients received a total of four semi-quantitative scores. 
Seventeen and thirteen possible dichotomized cutoffs could be 
obtained for each marker in the tumor (five-tiered scale) and the 
stromal (four-tiered scale) compartments, respectively. To visualize 
the prognostic impact of the investigated markers in relation to 
DSS, all potential dichotomized cutoffs from the semi-quantitative 
and digital analyses were plotted against P-values (Supplementary 
Figure S1). Due to superior prognostic information (Supplementary 
Figure S1), absolute reproducibility and ease of use, we decided to 
use digital counts in any subsequent analyses.
All potential cutoffs for digital TIL counts in the overall cohort, 
and in the LUSC and LUAD subgroups, are visualized in Figure 2. 
For simplicity of interpretation, dichotomization of the digital TIL 
counts was based on the cutoff yielding the lowest P-value in the 
overall cohort and then rounded to the nearest number divis-
ible by 50. The final cutoffs, in cells/mm2, were as follows: CD3 ≤ 
1000; CD4 ≤ 550; CD8 ≤ 500; CD20 ≤ 400; CD45RO ≤ 250. The most 
discriminating prognostic information was found for LUSC pa-
tients, which translated into the prognostic differences we see for 
most markers in the overall cohort. For LUAD, there was hardly 
any significant values for any of the examined markers.
CD3+, CD4+, CD8+, CD20+ and CD45RO+ TILs and their 
correlations with clinicopathological variables
The correlations between clinicopathological variables and 
the dichotomized markers are presented in Table  1. To sum-
marize, only a few reliable and significant correlations were ob-
served. Female gender was associated with high CD3 (P = 0.004), 
increasing age was associated with high CD4 (P  =  0.029) and 
increasing pStage was associated with CD4 (P  =  0.001), CD8 
(P = 0.015) and CD45RO (P = 0.029).
Figure 2. All possible dichotomized cutoffs for CD3, CD4, CD8, CD20 and CD45RO plotted against P-values indicating significance of DSS for all patient (A) and in the 
LUSC and LUAD histological subgroups (B and C). Vertical lines and numbers printed on the plot represents median and optimal cutoff values for each marker, respect-
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All markers were plotted against pStage to further ex-
plore the correlations between pStage and marker expression 
(Supplementary Figure S2). Overall, the number of positive im-
mune cells decreased with increasing pStage. This observation was 
most prominent for CD4 and CD8 and between pStages I/II and III.
The differences in the total number of detected cells, and 
the number of positive cells for each marker, were compared 
in the LUSC versus LUAD subgroups. No differences in the total 
number of cells (P = 0.36) or the number of CD8 (P = 0.56), CD20 
(P  =  0.57) and CD45RO (P  =  0.87) positive cells were observed. 
A  tendency toward more positive cells in the LUAD subgroup 
was observed for CD3 (P = 0.06) and CD4 (P = 0.04).
Survival analyses
Univariable survival analyses of the investigated markers are 
summarized in Figure 2 and Table 2. Briefly, CD3, CD4, CD8, CD20 
and CD45RO were all significant positive prognosticators of DSS 
in the overall cohort (P-values = <0.001, 0.007, <0.001, <0.001 and 
<0.001, respectively) and in the LUSC subgroup (P-values = 0.002, 
0.009, <0.001, 0.046 and 0.002, respectively), whereas only CD8 
and CD20 (P-values  =  0.04 and 0.003) were significant positive 
prognosticators of DSS in the LUAD subgroup.
Based on the results from the cutoff explorations and 
univariable survival analyses, CD8 and CD20, both with excellent 
immunohistochemistry antibodies (Figure 1), excellent prognostica-
tion in the overall cohort and in the LUSC subgroup and reasonable 
prognostication in the LUAD subgroup (Table 2; Figure 2) and within 
most pStages (Supplementary Figures S3 and S4), were selected for 
multivariable analyses alongside key clinicopathological variables. 
Multivariable survival models are presented in Table 3.
High number of CD8 TILs was an independent significant 
prognosticator of favorable prognosis in the overall cohort 
[hazard ratio (HR) 0.52, 95% confidence interval [CI] 0.39–0.69, 
P < 0.001] and in the LUSC subgroup (HR 0.41, 95% CI 0.26–0.62) 
P < 0.001), but not in the LUAD subgroup (HR 0.72, 95% CI 0.49–
1.07, P = 0.104).
High number of CD20 TILs was an independent prognosti-
cator of favorable prognosis in the overall cohort (HR 0.61, 95% CI 
0.40–0.94, P = 0.025), but not in the LUSC subgroup (HR 0.73, 95% 
CI 0.39–1.38, P = 0.334). In the LUAD subgroup (HR 0.56, 95% CI 
0.30–1.03, P = 0.06), a tendency toward significance was observed.
TNM-Immune cell score for NSCLC
Building on the results from the multivariable analyses, the in-
tegration of pStage and CD8 TIL level was explored. Figure 4A, 
D and G shows 5-year survival of patients, in the overall cohort 
and the LUSC and LUAD subgroups, stratified by pStage and 
CD8+ TILs. To build an integrated CD8 TNM, or TNM-I, groups 
with ≥80%, 60%–79%, 40%–59% and <40% five-year survival in 
the overall cohort were considered favorable (Fav), intermediate-
favorable (Int-Fav), intermediate poor (Int-Poor) and poor (Poor), 
respectively. Results are presented in Table 2 (univariable) and 
Table 3 (multivariable). The TNM-I was an independent signifi-
cant prognosticator for favorable prognosis in the overall cohort 
and in both the LUSC and LUAD subgroups.
Discussion
The immune contexture as a prognostic and/or 
predictive marker in NSCLC
In this article, we have explored the immune contexture in 
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quantitative evaluation of the main subsets of tumor infiltrating 
lymphocytes, in combination with pStage, we have shown that 
a TNM-Immune cell score for NSCLC patients is feasible. The re-
sulting score yields increased prognostic accuracy at the cost of 
a fairly simple diagnostic test. As in our previous studies, the 
prognostic impact of the TNM-I is considerably stronger in LUSC 
compared with LUAD patients.
Automated digital versus manual quantification 
of TILs
In previous studies, we have utilized a semi-quantitative scoring 
approach (12,14). In these studies, immune cells in different 
compartments (intraepithelial versus stroma) were considered 
separately. Using this approach, immune cells in intratumoral 
stroma was found to be the superior prognosticator. In the pre-
sent study, a digital scoring approach was applied and com-
pared with semi-quantitative scores. As expected, the digital 
and semi-quantitative scores were significantly correlated 
(Supplementary Table S1). However, the continuous variables 
provided by digital quantification allowed fine tuned cutoff se-
lection, which translated into additional prognostic information 
(Supplementary Figure S1) and superior multivariable models. 
Surprisingly, no difference in the prognostic impact of TILs 
was observed for the intraepithelial versus stromal compart-
ments (data not shown). Furthermore, once established, digital 
quantification has better reproducibility and allows higher 
throughput. Hence, digital scores were considered superior to 
semi-quantitative scores.
Choosing candidate markers for an Immune cell 
score for NSCLC patients
Given an optimized pre-analytic workflow, candidate markers 
for a clinically used test utilizing immunohistochemistry should 
be subject to careful antibody selection, and optimization on 
an automated platform for ease of use (28). The markers under 
consideration should show significant discrimination between 
study groups and exhibit excellent reproducibility (28). CD3, 
Figure 3. Disease-specific survival curves for ≤500 versus >500 CD8 TILs per mm2 and ≤400 versus >400 CD20 TILs per mm2 and their combination in (A, D and G) all 
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CD4, CD8, CD20 and CD45RO are all well validated and in rou-
tine clinical use. All markers exhibited stellar staining (Figure 1).
Comparing DSS data (Table  2; Supplementary Figures S1 
and S3), CD3+, CD8+ and CD45RO+ TILs are potential candidate 
markers for a TNM-I in the overall cohort, and in the LUSC sub-
group, while CD8+ and CD20+ TILs are most promising in the 
LUAD subgroup. Moreover, CD8/CD20 combinations were ex-
plored using survival curves (Figure 3G–I; Supplementary Figure 
S4J–L). From these figures, it is evident that no additional benefit 
is gained from combining CD8/CD20 versus CD8 alone. For 
LUSC and LUAD, the observed survival differences rely almost 
solely on CD8+ and CD20+ TILs, respectively. Similar observa-
tions were made when exploring other possible combinations 
(data not shown). In multivariable analyses, CD8+ TILs was an 
independent positive prognosticator in the overall cohort and 
in the LUSC subgroup, whereas CD20 was near significant in 
the LUAD subgroup. CD8+ TILs is the most promising candi-
date for at TNM-I from our previous studies and corroborated 
by the Immunoscore® for CRC (10,13,16,29). In addition, the op-
timal cutoff for CD8+ TILs was near median, yielding a sufficient 
number of patients in the high and low groups for the combin-
ation with pStage. Hence, CD8+ TILs were considered the best 
candidate marker for a TNM-I in NSCLC.
The clinical utilization of a TNM-Immune cell score 
for NSCLC patients
This study demonstrates, as a proof-of-concept, that digitally 
quantified CD8+ TIL density easily incorporates with pStage to 
form an TNM-Immune cell score for NSCLC. As a supplement 
to the established prognostic toolbox, the TNM-I could help 
identify patients in need of adjuvant treatment or, more im-
portantly, those who are not. As expected, the group with a fa-
vorable TNM-I (pStages IA and IB with a high CD8+ TIL density) 
exhibit excellent 5- and even 10-year disease-specific survival in 
our cohort (Figure 4; Tables 2 and 3; and Supplementary Figure 
Figure 4. Five-year disease-specific survival in each pStage stratified by CD8+ TILs and color coded into distinct subgroups with similar survival and disease-specific 
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S4). More interesting, are the results for patients classified as 
TNM-I intermediate-favorable: no difference in DSS is observed 
between patients in pStage IA with low CD8+ TIL density and 
pStage IIA and B with high CD8+ TIL density. As pStage II is the 
recommended threshold for adjuvant chemotherapy (30), the 
TNM-I may force us to rethink this practice, either by considering 
adjuvant therapy to all TNM-I intermediate-favorable patients, 
thus including pStage IA/CD8+ low, or by moving the threshold 
to TNM-I intermediate-low (Figure  4; Supplementary Figure 
S4). Applying the TNM-I approach could potentially reduce the 
number needed to treat and increase adjuvant treatment effi-
cacy. Additionally, as immunotherapy is gradually implemented 
in earlier stages of treatment (neo/adjuvant), it will be of great 
interest to see whether the TNM-I can add valuable prognostic/
predictive information in this aspect as well.
Histology-specific adaptations of the TNM-I 
in NSCLC
The impact of CD8+ TIL density, while showing an impact in 
LUAD patients, is mainly found in LUSC patients, who are the 
main drivers of the results in the overall cohort. In addition, 
based on Figure 4, it is likely that a TNM-I for LUSC patients 
will be further improved by moving pStage II high CD8+ TIL 
density patients to the TNM-I favorable group. Interestingly, 
the mean density of some (CD3+ and CD4+), but not all (CD8+, 
CD20+ and CD45RO+) TILs were higher in LUAD compared 
with LUSC patients. This finding may indicate different im-
mune responses in these two histological entities and war-
rant further investigation. For LUAD patients, although the 
CD8+ TIL-based TNM-I yields superior prognostication when 
compared with the conventional TNM, the results for CD20+ 
TILs are especially interesting. The observed prognostic im-
pact of CD20+ TILs indicates that this cell type is involved in 
immune-activation in LUAD patients. CD20+ TILs are known to 
cluster in tertiary lymphoid structures. Based on recent publi-
cations in other cancer forms (31,32), it is pertinent to specu-
late if this result indicates similar processes in LUAD patients. 
However, CD20+ TILs were not significant in multivariable ana-
lysis (Table 3). A plausible explanation is that, because of their 
relative scarcity, the number of CD20+ TILs is not reliably es-
timated in TMAs. We are currently exploring the prognostic 
impact of tertiary lymphoid structures in NSCLC using whole 
slide images (to be published).
Future perspectives
The applicability of the TNM-I, presented as a result from 
this exploratory study, needs to be confirmed. Our research 
group has initiated a large multi-center study with an aim 
of implementing a TNM-I for NSCLC (NCT03299478). The pre-
sented TNM-I will be tested in this cohort upon study com-
pletion. If rapid implementation is warranted, confirmation in 
large, recent retrospective cohorts may be conducted. As sug-
gested in the previous section, future studies should include 
sufficient numbers to explore histology-specific adaptations 
of the TNM-I.
Furthermore, in light of the recent advances in therapies 
directly influencing the activation and prolongation the tumor 
immune response, the concept of an Immune cell score gives 
promise beyond being a mere addition to a prognostic score. 
Active in situ immune-activation, measured using the CD8+ TIL 
density, in addition to or in place of PD-L1, may identify patients 
for whom immune-related therapy is likely to be beneficial. This 
could prove a pivotal clinical aspect of the TNM-I, which would 
benefit patients not only with regard to outcomes, but also alle-
viate the increasing financial burden of treatment, as recognized 
by ASCO (33).
Conclusions
Recently published evidence suggests that the introduction of a 
TNM-I for NSCLC will add meaningful prognostic stratification 
on the already excellent TNM system (12,13,16). We present data 
confirming that CD8+ TIL density is the most robust candidate 
for a TNM-I in NSCLC, as its incorporation improves upon the 
current TNM systems ability to predict disease-specific survival 
for NSCLC patients. Corroborating previous studies, the most 
pronounced prognostic effect of CD8+ TILs and the proposed 
TNM-I is observed in LUSC patients. However, contrary to prior 
studies, a non-negligible effect is also observed in LUAD pa-
tients. Furthermore, we show that CD8+ TILs may be automat-
ically detected in digital TMAs and subsequently interpreted by 
freely available open source software, thus avoiding common 
hurdles for biomarker implementation such as additional cost 
and added complexity.
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Figure S1. All possible dichotomized cutoffs for CD3, CD4, CD8, 
CD20 and CD45RO plotted against P-values indicating signifi-
cance of disease-specific survival for digital scores (A) and semi-
quantitative scores in stroma (B) and tumor (C). Vertical lines 
and numbers printed on the plot represents median and optimal 
cutoff values for each marker, respectively. For ease of interpret-
ation, curves are slightly smoothed whenever possible (small dots 
represent the actual data points). Abbreviations: DS, digital score; 
SQ, semi-quantitative; DSS, disease-specific survival; LUSC, lung 
squamous cell carcinoma; LUAD, lung adenocarcinoma
Figure S2. The median number of CD3, CD4, CD8, CD20 and 
CD45RO positive cells stratified by pStage (Two sided Wilcoxon 
rank-sum test). **P < 0.01, *P < 0.05.
Figure S3. All possible dichotomized cutoffs for CD3, CD4, CD8, 
CD20 and CD45RO plotted against P-values indicating signifi-
cance of disease-specific survival in pStage I  (A), II (B) and III 
(C). Dashed vertical lines represent median values for each 
marker, respectively. For easier interpretation all curves are 
slightly smoothened (small dots represent the actual data 
points). Abbreviations: DS, digital score; SQ, semi-quantitative; 
OS, overall survival; LUSC, lung squamous cell carcinoma; LUAD, 
lung adenocarcinoma
Figure S4. Disease-specific survival curves for pStage I-III 
(panels A–C), and for ≤500 vs >500 CD8 TILs per mm2 and ≤ 400 vs 
> 400 CD20 TILs per mm2 and their combinations in pStage I-III, 
panels D-F, G-I and J-L, respectively. Abbreviations: TILs, tumor 
infiltrating lymphocytes; LUSC, lung squamous cell carcinoma; 
LUAD, lung adenocarcinoma.
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